# Trial of Ixazomib for Kaposi Sarcoma

> **NCT04305691** · PHASE2 · RECRUITING · sponsor: **AIDS Malignancy Consortium** · enrollment: 41 (estimated)

## Conditions studied

- Kaposi Sarcoma
- Skin

## Interventions

- **DRUG:** Ixazomib Citrate
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04305691
- **Lead sponsor:** AIDS Malignancy Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-07
- **Primary completion:** 2029-03-15
- **Final completion:** 2029-03-15
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04305691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04305691, "Trial of Ixazomib for Kaposi Sarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04305691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*